Clinical trials: Persistent Proteinuria With Type II Diabetes
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
- Trial name
- NCT00913393
- Testing
- FG-3019
- Where
- 28 sites in United States
- Volunteers
- 46 people
- Sponsor
- Kyntra Bio
Diabetic Nephropathy, Persistent Proteinuria With Type II Diabetes
Renal Denervation in Diabetic Nephropathy
The DERENEDIAB study is a proof-of-concept, multi-center, prospective, open, randomized, controlled study of the effectiveness of renal denervation in addition to standardized medical treatment compared to medical treatment alone…
- Trial name
- DERENEDIAB (NCT01588795)
- Testing
- Percutaneous renal denervation and TMNS, Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetic Nephropathy
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE…
- Trial name
- NCT00462202
- Testing
- sulodexide
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Keryx Biopharmaceuticals